Vanda Seeks FDA Approval for Novel GPP Drug, Aims for Share of Orphan Disease Market

WASHINGTON, DC – December 15, 2025 – Vanda Pharmaceuticals has taken a significant step toward addressing a severe and rare skin disease, announcing today the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for imsidolimab. The novel therapy targets generalized pustular psoriasis (GPP), a debilitating and life-threatening autoinflammatory condition with historically limited treatment options. The company has requested a priority review, which, if granted, could shorten the review timeline to six months and potentially lead to an FDA approval as early as mid-2026.

This submission positions imsidolimab as a potential new cornerstone in Vanda's growing portfolio of treatments for rare orphan disorders. It represents not only a beacon of hope for thousands of GPP sufferers worldwide but also a calculated strategic maneuver to capture a key segment of the lucrative rare disease market, backed by promising clinical data and long-term patent protection extending into the late 2030s.

A Lifeline for a Devastating Disease

Generalized pustular psoriasis is far more than a simple skin condition. It is a rare, chronic, and unpredictable systemic disease characterized by sudden and widespread flares of painful, sterile pustules. These episodes are often accompanied by systemic symptoms like high fever, debilitating fatigue, intense itching, and joint pain, frequently requiring hospitalization. If left unmanaged, GPP flares can lead to life-threatening complications, including severe infections, heart and kidney failure, and acute respiratory distress syndrome.

The patient burden is immense. Beyond the acute physical suffering, individuals with GPP face significant psychological distress, including anxiety and depression. Research indicates that over 80% of patients experience persistent symptoms even between flares, and the disease’s rarity often leads to misdiagnosis and delays in receiving appropriate care. Until 2022, no treatments were specifically approved for GPP, forcing physicians to rely on off-label systemic drugs like methotrexate and cyclosporine, which offer limited efficacy and can carry significant side effects.

The approval of spesolimab (Spevigo) marked a turning point as the first therapy specifically for GPP. However, significant unmet needs remain. Many dermatologists still consider the current therapeutic landscape inadequate for preventing new flares or managing the chronic nature of the disease. It is into this environment that Vanda aims to introduce imsidolimab, offering another targeted option for a patient population in desperate need of effective, long-term solutions.

Unpacking the Clinical Promise of Imsidolimab

Imsidolimab is a fully humanized monoclonal antibody that functions as an IL-36 receptor antagonist. This mechanism is highly targeted, as it directly inhibits the inflammatory pathway driven by the interleukin-36 cytokine, a key culprit in GPP. Many GPP patients have a genetic mutation that impairs the body's natural ability to regulate this pathway, and imsidolimab works to counteract this deficiency.

The BLA submission is anchored by robust data from two global Phase 3 trials, GEMINI-1 and GEMINI-2, which demonstrated both rapid efficacy and sustained long-term control.

In the GEMINI-1 study, which evaluated the drug's ability to treat acute flares, 45 patients were randomized to receive a single intravenous dose of imsidolimab or a placebo. The results were striking: at the four-week mark, 53% of patients treated with imsidolimab achieved clear or almost clear skin. This was a statistically significant improvement over the 13% of patients who saw similar results in the placebo group.

Perhaps more compelling is the data from the GEMINI-2 maintenance study. Responders from the first trial were enrolled in a long-term study lasting up to 116 weeks, or approximately two years. Patients received monthly subcutaneous doses of imsidolimab or a placebo. The results provided powerful evidence of durable disease control: 100% of patients on active imsidolimab maintenance therapy remained free of flares and maintained clear or almost clear skin throughout the study period. In stark contrast, 63% of patients in the placebo group experienced a flare. Across both studies, imsidolimab demonstrated a favorable safety profile, with no treatment-related serious adverse events reported.

A Strategic Play in a Competitive Market

With this submission, Vanda is entering a specialized but competitive field. Imsidolimab’s primary competitor is spesolimab, which shares the same IL-36 receptor antagonist mechanism. As the first-to-market therapy, spesolimab has already established a foothold. However, imsidolimab's impressive maintenance data from the GEMINI-2 trial could be a key differentiator, appealing to physicians and patients focused on long-term flare prevention—a critical unmet need.

"The submission of the BLA for imsidolimab marks a critical milestone in our efforts to bring this innovative therapy to patients suffering from GPP," said Mihael H. Polymeropoulos, M.D., President and CEO of Vanda Pharmaceuticals. "Imsidolimab builds on our growing expertise in rare orphan disorders and our anti-inflammatory portfolio... We look forward to potential FDA approval and leveraging our commercial infrastructure to address this debilitating condition."

The company’s request for priority review underscores the seriousness of GPP. This FDA designation is reserved for drugs that, if approved, would represent a significant improvement in the treatment of a serious condition. Given GPP's status as a rare orphan disease with a high unmet need, the request has a strong basis. Approval would grant Vanda access to a market protected by Orphan Drug Designation, which provides seven years of market exclusivity in addition to the drug's patent life.

This move is also financially strategic. In early 2025, Vanda secured exclusive global rights to imsidolimab from its developer, AnaptysBio, in a deal that included a $10 million upfront payment and up to $35 million in future milestones, plus a 10% royalty on net sales. This structure allows Vanda to acquire a late-stage, de-risked asset while sharing future success with its partner. With patent and regulatory exclusivity expected to last into the late 2030s, imsidolimab represents a long-term revenue opportunity that aligns perfectly with Vanda's focus on building a durable franchise in rare diseases.